Splenectomy before Allogeneic Hematopoietic Stem-cell Transplantation for Myelofibrosis: Two Cases

Download Citation in txt Download Citation in bib Download Citation in ris

Author Info

Zhengxiang Yang Aibin Zhang Xiaoyu Lai Luxin Yang Yishan Ye Qingna Guo Yibo Wu He Huang Yi Luo Lizhen Liu

Corresponding Author

Lizhen Liu
Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

A B S T R A C T

Myelofibrosis (MF) is a clonal hematological malignancy characterized by splenomegaly, systemic symptoms, myelofibrosis, and a tendency to transform into acute leukemia. MF treatment includes anemia treatment, hydroxyurea, JAK inhibitors (JAKi) allogeneic hematopoietic stem cell transplantation (allo-HSCT), among which allo-HSCT is the only possible cure for MF. The effect of splenomegaly on the prognosis of allo-HSCT with myelofibrosis and whether splenic treatment is needed before transplantation has not been determined. A recent retrospective study from the EBMT working group found that splenectomy significantly reduced transplant-related non-recurrent mortality and did not increase the risk of disease recurrence in MF patients with pre-transplant splenomegaly. Two cases of MF splenectomy combined with allo-HSCT are reported.

Article Info

Article Type

Case Report

Publication history

Received: Mon 13, May 2024
Accepted: Tue 11, Jun 2024
Published: Tue 30, Jul 2024

Copyright

© 2023 Lizhen Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Hosting by Science Repository.
DOI: 10.31487/j.SCR.2024.02.01